Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07375095 · ClinicalTrials.gov registry record · NA

A Study of a Sleep Supplement to Improve Sleep in Women Going Through Menopause

A NA study of Sleep Disturbance, sponsored by Bonafide Health.

Completed
Registry status
NA
Development phase
128
Enrollment target
1
Study location

NCT07375095: Completed NA study of Sleep Disturbance, sponsored by Bonafide Health.

NCT07375095 is a NA study of Sleep Disturbance that has completed, run by Bonafide Health. The registered enrollment target is 128 participants, below the 176-participant average among 56 other Sleep Disturbance trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07375095, a NA study of Sleep Disturbance, has completed, sponsored by Bonafide Health.

COMPLETED
Registry status
NA
Development phase
128 participants
Enrollment target
1
Study location

Study Summary

This study evaluated whether a daily dietary sleep supplement could improve sleep in women aged 40 to 65 who experience moderate sleep disturbances during menopause. Participants were randomly assigned to take either the supplement or a placebo for about three weeks. All study visits were conducted virtually. Sleep was assessed through daily diaries and weekly questionnaires measuring sleep quality, nighttime awakenings, daytime alertness, and mood. The study's goal was to compare changes between the supplement and placebo groups and to assess safety and tolerability during the study period.

Primary Outcome

Change from baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS®) Sleep Disturbance Short Form 8b T-score, a validated patient-reported outcome measure assessing perceived sleep quality, difficulty falling or staying asleep, and overall sleep satisfaction over the prior 7 days. The PROMIS Sleep Disturbance Short Form 8b yields raw scores ranging from 8 to 40, which are converted to standardized T-scores ranging from 28.9 to 76.5. Higher T-scores indicate greater slee

Conditions Studied

Interventions

  • DRUG Placebo
  • DIETARY_SUPPLEMENT Sleep Supplement

Study Locations (1)

New York

  • Bonafide Health, LLC - Harrison

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2023-10-10
Est. Completion 2024-04-07
Phase NA
Bonafide Health

5 total trials

What the finished NCT07375095 record still lists

NCT07375095 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 176-participant average among 56 other Sleep Disturbance trials with a reported enrollment target (27% lower).

The record links to 1 condition, with Sleep Disturbance appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07375095 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT07375095 about?

NCT07375095 is a clinical study titled "A Study of a Sleep Supplement to Improve Sleep in Women Going Through Menopause". This study evaluated whether a daily dietary sleep supplement could improve sleep in women aged 40 to 65 who experience moderate sleep disturbances during menopause. Participants were randomly assigned to take either the supplement or a placebo for about three weeks. All study visits were conducted ...

What is the current status of trial NCT07375095?

This trial is currently completed. It is a NA study. The enrollment target is 128 participants. The study started on 2023-10-10. Estimated completion is 2024-04-07.

What conditions does trial NCT07375095 study?

This clinical trial studies the following conditions: Sleep Disturbance.

What interventions are being tested in trial NCT07375095?

The interventions under investigation include: Placebo (DRUG), Sleep Supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07375095?

This trial is sponsored by Bonafide Health, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07375095 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sleep Disturbance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07375095's enrollment target sits among peer trials

128 18th of 56 higher than 39 of 56 other Sleep Disturbance trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sleep Disturbance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02870738 · 128 participants · Phase 2

    Bladder Directed vs. Pelvic Floor Therapy in IC/BPS

  • NCT03294460 · 128 participants · Phase 1

    Nicotinic Receptor Genetic Variation and Alcohol Reward

  • NCT04149977 · 128 participants · NA

    Blood Flow Restriction Therapy in Lower Limb Extensor Injuries

  • NCT04373057 · 128 participants · Phase 1

    Prebiotic Galacto-oligosaccharide and Acute GVHD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07375095, the US trial registry maintained by the National Library of Medicine. NCT07375095 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.